Form 4: LivaNova Executive Reports Equity Vesting and New Grants

LivaNova PLC's President of Global Epilepsy, Stephanie Bolton, reported the vesting of equity awards and new grants of restricted and performance stock units.

Summary

• Stephanie Bolton, President, Global Epilepsy at LivaNova PLC, reported transactions on March 30, 2026.
• Acquired 17,815 ordinary shares from the settlement of vested restricted stock units (RSUs) and performance stock units (PSUs).
• Disposed of 8,377 ordinary shares at a price of $61.27 per share to satisfy tax liabilities related to the vesting.
• Following these transactions, Bolton beneficially owns 22,189 ordinary shares.
• Multiple tranches of RSUs and PSUs vested, including 457, 1,330, 1,229, and 2,343 RSUs.
• Performance Stock Units (PSUs) related to 2023-2025 performance periods also vested, including 3,243 units based on Free Cash Flow (FCF), 3,156 units based on Return on Investment Capital (ROIC), and 6,057 units based on relative Total Shareholder Return (rTSR).
• New grants were issued on March 30, 2026, including 8,976 RSUs vesting over three years, with the first installment on March 30, 2027.
• Additional new grants of PSUs were issued, totaling 2,992 units each, tied to revenue growth, rTSR, and adjusted EPS for the 2026-2028 performance period, vesting on March 30, 2029.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates strong performance against key financial and shareholder return metrics, leading to above-target vesting of performance awards for a key executive. The new grants further align executive interests with future company success.

Positives

• Performance Stock Units (PSUs) for the 2023-2025 period vested above target: 122.0% for Free Cash Flow (FCF), 118.71% for Return on Investment Capital (ROIC), and 113.89% for relative Total Shareholder Return (rTSR), indicating strong company performance against these metrics.
• The executive received new grants of RSUs and PSUs, aligning her interests with long-term company performance and shareholder value.

Negatives

• 8,377 ordinary shares were disposed of to cover tax liabilities, representing a reduction in direct shareholding.

Future Outlook

The filing indicates future equity compensation for the executive, with new RSU grants vesting annually through March 30, 2029, and new PSU grants tied to the company's revenue growth, relative total shareholder return, and adjusted earnings per share for the 2026-2028 performance period, vesting on March 30, 2029.

Industry Context

StockSavvy.ai notes that the vesting of performance-based equity awards above target for Free Cash Flow, ROIC, and rTSR suggests LivaNova PLC has demonstrated strong operational and shareholder value creation relative to its internal goals and market peers during the 2023-2025 period. The continued granting of long-term incentive awards to key executives like the President of Global Epilepsy is a standard practice in the medical technology industry to align management incentives with long-term strategic objectives and shareholder interests.

Comparison to Industry Standards

• The use of Free Cash Flow, Return on Investment Capital, and relative Total Shareholder Return as performance metrics for PSUs is consistent with best practices in executive compensation across the medical device and broader healthcare industry, aiming to incentivize both operational efficiency and shareholder returns.
• The vesting percentages (122.0% for FCF, 118.71% for ROIC, 113.89% for rTSR) indicate LivaNova's performance exceeded the targets set by the 2022 Plan Administrator, which is a positive signal compared to companies that might struggle to meet even threshold performance levels for executive compensation.

Stakeholder Impact

• Shareholders: The above-target vesting of performance units suggests effective management performance in driving Free Cash Flow, Return on Investment Capital, and relative Total Shareholder Return, which is generally positive for shareholder value. The new grants reinforce long-term alignment.
• Employees: The incentive award plans (2015 Plan, 2022 Plan, First A&R 2022 Plan, Second A&R 2022 Plan) provide a framework for executive compensation, which can influence broader compensation strategies and employee morale.

Next Steps

• Annual vesting installments for RSUs granted on March 30, 2026, will occur through March 30, 2029.
• PSUs granted on March 30, 2026, will vest on March 30, 2029, based on LivaNova's revenue growth, rTSR, and adjusted EPS performance for the 2026-2028 period.

Key Dates

Recommendation

This Form 4 reports routine executive compensation events, including the vesting of equity awards and new grants, which are generally expected and do not typically signal a significant change in the company's fundamental outlook or warrant an immediate 'buy' or 'sell' action. The above-target performance for vested PSUs is a positive indicator, but the filing itself is not a catalyst for a strong recommendation change.

Keywords

LivaNova PLC, LIVN, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Performance Stock Units, Executive Compensation, Share Vesting, Tax Withholding